News Column

RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology

July 9, 2014

By a News Reporter-Staff News Editor at Biotech Week -- As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone, new research into the drug's potential could soon dramatically expand the drug's market and usage (see also Rainbow Coral Corp.).

Naltrexone has been approved by the FDA for use in combatting alcohol and heroin addiction by fine-tuning the brain's chemical rewards system to help reduce cravings. But new research into the drug's properties has revealed promising applications for the treatment of autoimmune diseases and chronic pain.

Last month, researchers at Pennsylvania State University, Hershey, showed that the opioid-receptor antagonist modifies established disease in a mouse model of relapsing-remitting multiple sclerosis. Preliminary studies have also suggested that Naltrexone may be an effective treatment for patients with fibromyalgia, Crohn's Disease, lupus, rheumatoid arthritis and other illnesses, as well.

As the usefulness of the drug is carefully reexamined in the treatment of a number of diseases, RBCC is working to make Naltrexone easier to administer effectively than ever before. The company formed a joint venture with TheraKine, Ltd., to develop a sustained-release technology poised to vastly improve patients' use of Naltrexone. Phase I of the joint venture's research established excellent compatibility between the drug and TheraKine's hydrophobic injection matrix, as well as a highly promising release profile. Phase II focused on micronization of the technology as well as extension of its sustained release time.

This summer, RBCC will focus on demonstrating the new technology's readiness for market.

RBCC's biotech division, Rainbow BioSciences, is working with partners such as TheraKine to capitalize on the incredible growth of the global drug delivery market by delivering new medical and research technology innovations in order to compete alongside companies such as Bristol Myers Squibb Co. (BMY), Biogen Idec Inc. (BIIB), Abbott Laboratories (ABT) and Valeant Pharmaceuticals International (VRX).

Keywords for this news article include: Therapy, Technology, Rainbow Coral Corp., Marketing and Licensing Agreements.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters